rhBMP-2/CRM/CD HORIZON® Spinal System Pivotal Study (CRM)
A Prospective, Randomized Clinical Investigation of rhBMP-2 and Compression Resistant Matrix With the CD HORIZON® Spinal System for Posterolateral Lumbar Fusion in Patients With Symptomatic Degenerative Disc Disease
Sponsor: Medtronic Spinal and Biologics
This PHASE3 trial investigates Degenerative Disc Disease and is currently completed. Medtronic Spinal and Biologics leads this study, which shows 8 recorded versions since 2002 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jun 2023 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jun 2023 [monthly]
Completed PHASE3
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Mar 2002
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Medtronic Spinal and Biologics
For direct contact, visit the study record on ClinicalTrials.gov .